Clinical Trials Logo

Clinical Trial Summary

This is a prospective observational cohort study designed to collect data on patients who received REBYOTA™ for the prevention of rCDI in the routine care setting. As all data collected for this study are observational, the decision to prescribe REBYOTA™ is at the treating physician's discretion and independent from the decision to enroll the patient in the study. Data will be collected from patients' medical records after obtaining informed consent. Data about clinical history, CDI events (primary and recurrent: severity, treatment), CDI-related symptoms, treatments, medical procedures, Adverse Events(AEs), and healthcare resource utilization (i.e., hospitalizations and re-admissions) will be collected through 6 months of follow-up from the date of REBYOTA™ administration.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05835219
Study type Observational
Source Ferring Pharmaceuticals
Contact Global Clinical Compliance
Phone +1 833-548-1402 (US/Canada)
Email DK0-Disclosure@ferring.com
Status Recruiting
Phase
Start date June 19, 2023
Completion date August 1, 2025